Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.
Timothy M. Schmidt, MD, an assistant professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the clinical implications of AMG 420 in multiple myeloma.
AMG 420 demonstrated proof of concept for using bispecific antibodies in multiple myeloma, says Schmidt. The agent showed remarkable responses with a significant depth and durability of response.
However, because of the design of the drug’s linker, AMG 420 has a short half-life and is metabolized quickly by the patient, Schmidt says. As such, treatment with the agent requires continuous infusion via a pump. Although feasible, this method of administration is not convenient for patients or providers, Schmidt explains. Novel bispecific antibodies being developed may be able to overcome this limitation, concludes Schmidt.